List of Excipients in Branded Drug TYVASO DPI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
United Therapeutics Corporation	TYVASO DPI	treprostinil	66302-616	FUMARYL DIKETOPIPERAZINE

Tyvaso DPI Excipient Strategy and Commercial Opportunities

Last updated: August 19, 2026

Tyvaso DPI uses a platform-based dry-powder formulation built around treprostinil and fumaryl diketopiperazine, or FDKP. The excipient is commercially important because it supports powder formation, aerosol dispersion, lung delivery, and device compatibility. The strategy creates barriers for conventional generic development, but it also opens opportunities in excipient supply, particle engineering, inhaler platforms, alternative formulations, and non-U.S. manufacturing.

What excipients are used in Tyvaso DPI?

Tyvaso DPI contains treprostinil and FDKP as the principal formulation components. The product is supplied in single-dose cartridges and administered through the Tyvaso DPI inhaler. The FDA prescribing information identifies FDKP as the inactive ingredient used in the dry-powder formulation.[1]

Product attribute	Tyvaso DPI characteristic
Active ingredient	Treprostinil
Dosage form	Inhalation powder
Delivery route	Oral inhalation
Excipient	Fumaryl diketopiperazine, or FDKP
Device	Tyvaso DPI inhaler
Sponsor	United Therapeutics Corp.
Technology partner	MannKind Corp.
FDA approval	May 2022
Indications	Pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease
Administration	Four times daily
Dose strengths	16, 32, 48 and 64 micrograms per cartridge

The FDKP component is not a conventional lactose carrier. It is an engineered inhalation excipient associated with MannKind's Technosphere platform. FDKP self-assembles into microparticles that can carry drug and disperse into the lungs when inhaled.[2]

That distinction matters for generic competition. A lactose-based dry-powder inhaler would not necessarily replicate Tyvaso DPI's particle morphology, aerodynamic behavior, emitted dose, or lung deposition. A competing applicant could use a different formulation, but it would need to demonstrate equivalent performance and clinical effect through the applicable FDA pathway.

How does FDKP work in the Tyvaso DPI formulation?

FDKP performs several formulation functions:

1. It forms the structural matrix for the inhalable particles.
2. It supports high dispersibility and low-density aerosol behavior.
3. It enables drug loading without a large conventional carrier fraction.
4. It is compatible with MannKind's inhaler and cartridge system.
5. It may improve delivery of treprostinil to the deep lung.

The principal commercial value is the combination of excipient and particle-engineering know-how. FDKP alone is not the entire barrier. The formulation process, particle size distribution, drug loading, drying conditions, powder handling, cartridge fill, inhaler resistance, and dose-metering controls are also relevant.

A generic manufacturer would need to reproduce or adequately match:

• Mass median aerodynamic diameter
• Fine-particle fraction
• Emitted dose
• Delivered dose uniformity
• Moisture content
• Particle morphology
• Powder cohesion and flow
• Cartridge stability
• Device resistance and pressure-drop profile
• Treprostinil chemical stability
• Regional lung deposition

The formulation therefore has a platform-dependent quality profile. Conventional excipient substitution may be technically possible, but it would not be a simple inactive-ingredient change.

What is the commercial role of the Tyvaso DPI excipient strategy?

The excipient strategy supports United Therapeutics' transition from nebulized Tyvaso to a more convenient inhaled product. Tyvaso DPI reduces administration burden compared with the original nebulizer-based formulation and provides a cartridge-based, portable delivery system.

The economic value comes from four sources:

Commercial lever	Impact
Reduced administration burden	Supports conversion from nebulized Tyvaso
Proprietary formulation platform	Raises development cost for competing inhaled products
Device-formulation integration	Increases switching friction
Lifecycle management	Extends franchise value beyond the original nebulized product

Tyvaso DPI is not merely a reformulation of the same product. It changes the delivery platform while retaining treprostinil as the active ingredient. That creates a product-level differentiation strategy in a market where adherence, portability, treatment time, and device usability affect prescribing decisions.

United Therapeutics markets Tyvaso DPI for patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The broader Tyvaso franchise generated more than $1 billion in annual product sales in the 2023 period, making inhalation technology and excipient supply strategically material to the company.[3]

What patents protect Tyvaso DPI and its excipient platform?

Tyvaso DPI is likely protected through a layered estate rather than a single composition patent. The relevant categories include:

FDKP and Technosphere platform patents

MannKind has developed patent families covering FDKP chemistry, microparticle formation, drug loading, pulmonary delivery, and inhaler systems. These patents can protect the underlying platform across multiple active ingredients and product candidates.

Platform patents may have value beyond Tyvaso DPI because they can cover:

• FDKP particle compositions
• Drug-embedded microparticles
• Drying and manufacturing processes
• Inhaler operation
• Cartridge configurations
• Powder dispersion systems
• Combination products involving FDKP and specific drugs

Treprostinil dry-powder formulation patents

United Therapeutics and its partners may pursue claims directed to treprostinil inhalation powders, dose ranges, particle properties, and delivery methods. Such claims are narrower than broad platform claims but can provide product-specific protection.

Device and cartridge patents

The Tyvaso DPI system may also rely on patents covering:

• Single-dose cartridge geometry
• Cartridge sealing
• Dose release
• Airflow pathways
• Inhaler actuation
• Powder deaggregation
• Device resistance
• User interfaces

The combined estate can make an alternative product difficult to design around even when a competitor avoids the same excipient.

The FDA Orange Book is the relevant source for patents listed against the approved NDA. Orange Book listings can include formulation, method-of-use, and device patents, but they do not capture every patent that may be asserted in commercial litigation. Platform patents, manufacturing patents, and patents not listed for the NDA may remain relevant to freedom-to-operate analysis.[4]

When does Tyvaso DPI lose exclusivity?

Tyvaso DPI's principal regulatory exclusivity began with its May 2022 approval. As a new drug, it received five years of New Chemical Entity exclusivity if the active ingredient qualified for NCE treatment. That period generally prevents submission of an ANDA relying on the product's approval for five years, subject to a Paragraph IV exception beginning after four years.[5]

The commercial exclusivity timeline is therefore layered:

Protection	Approximate timing
FDA approval	May 2022
Five-year NCE exclusivity	Through approximately May 2027
Earliest standard Paragraph IV ANDA filing window	Approximately May 2026
Pediatric exclusivity	Depends on FDA grant and timing
Patent expiry	Depends on listed patents, patent-term adjustment and any extension
Generic launch	Earliest date depends on patents, litigation and settlement terms

The original Tyvaso product and Tyvaso DPI are separate FDA products with different delivery systems. Patent expiry for nebulized Tyvaso does not automatically establish a legally permissible launch date for a dry-powder treprostinil product.

A generic competitor could pursue:

• An ANDA for a product determined to be pharmaceutically and therapeutically equivalent
• A 505(b)(2) application using published data and bridging studies
• A separate inhaled treprostinil product with a distinct device or formulation
• A combination-product pathway with a non-FDKP excipient system

The more a competitor departs from Tyvaso DPI's formulation and device, the greater the risk that an ANDA will not be sufficient.

Are there Paragraph IV challenges to Tyvaso DPI?

A Paragraph IV challenge would require an ANDA applicant to certify that an Orange Book-listed patent is invalid, unenforceable, or not infringed. The challenge could trigger patent litigation within 45 days of notice to the NDA holder.[5]

The practical obstacles are significant:

• Dry-powder inhalers require complex equivalence testing.
• Device performance must be matched or legally addressed.
• Inhaled products can require comparative aerodynamic and clinical evidence.
• FDKP and the Technosphere platform may create overlapping patent exposure.
• A product that uses a different excipient may fall outside the ANDA framework.
• A 30-month stay could delay approval while litigation proceeds.

A Paragraph IV strategy is more attractive for a product that closely matches Tyvaso DPI's active ingredient, dose strengths, delivery profile, and administration schedule. A differentiated product using another carrier or particle-engineering technology may avoid some claims but face a higher regulatory burden.

No publicly established generic launch date should be assumed solely from the five-year NCE timeline. The relevant date depends on Orange Book listings, patent-term calculations, litigation outcomes, settlement restrictions, and FDA review.

What formulation patents are most commercially important?

The highest-value formulation claims are likely to be those that connect excipient identity with measurable aerosol performance. Broad claims to treprostinil powder may be vulnerable to prior-art attacks. Claims tied to defined particle attributes and performance can be more difficult to invalidate if they reflect a reproducible product profile.

Important claim areas include:

Excipient composition

Claims may cover treprostinil combined with FDKP at specific ratios or in a defined particle structure. These claims can be difficult to design around if FDKP is essential to achieving the product's target aerosol properties.

Particle engineering

Claims may focus on particle size, density, morphology, porosity, drug distribution, and aerodynamic diameter. These properties affect both product performance and manufacturing controls.

Manufacturing process

Spray drying, solvent selection, feed concentration, drying temperature, and post-processing may determine whether the finished powder meets release specifications. Process patents can be valuable even when composition claims are narrow.

Device-formulation combination

A claim directed to a specific cartridge, powder, and inhaler combination may create a stronger barrier than a formulation claim considered alone.

Method of use

Tyvaso DPI labeling covers treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Method-of-use patents could address dose escalation, administration frequency, patient populations, or treatment regimens. Such patents are relevant to skinny-label generic strategies, although enforcement depends on the precise claim language and labeled use.

How strong is the Tyvaso DPI patent estate?

The estate is strongest where four elements overlap:

1. FDKP-based particle technology
2. Treprostinil-specific formulation claims
3. Device and cartridge claims
4. Manufacturing know-how and process controls

The estate is weaker against a fully independent inhaled treprostinil platform that uses a different excipient, different particle architecture, and different inhaler. That product would face more development risk but could reduce dependence on MannKind's intellectual property.

Competitive approach	Patent exposure	Regulatory burden	Commercial probability
FDKP-based Tyvaso DPI copy	High	Moderate to high	Dependent on ANDA feasibility
Non-FDKP dry powder	Lower to moderate	High	Technically possible
Nebulized treprostinil generic	Separate estate and device issues	Moderate	More direct for legacy Tyvaso
Treprostinil soft mist inhaler	Potentially lower formulation overlap	High	Differentiated
Inhaled treprostinil suspension	Lower FDKP exposure	Moderate to high	Requires device and clinical differentiation
Biosimilar	Not applicable	Not applicable	Treprostinil is a small molecule

What commercial opportunities exist for excipient suppliers?

FDKP is the most direct excipient opportunity. A qualified supplier could target:

• FDKP raw material production
• Pharmaceutical-grade purification
• Controlled particle engineering
• GMP analytical testing
• Stability and impurity profiling
• Dual-source supply qualification
• Regional manufacturing
• Process development for new FDKP drug products

The opportunity is constrained by intellectual property and customer concentration. A supplier would need more than chemical manufacturing capability. It would need validated control over particle attributes and a regulatory package suitable for an inhaled product.

Other opportunities include excipients that compete with FDKP in inhaled powder systems:

• Phospholipid-based carriers
• Leucine and amino-acid dispersibility enhancers
• Sugars and sugar alcohols
• Spray-dried polymers
• Porous inorganic or composite carriers
• Lipid nanoparticles
• Engineered low-density particles

The strongest market position may come from excipient-plus-process packages rather than commodity excipient sales. Inhalation products are sensitive to supplier changes because small changes in moisture, morphology, density, or surface chemistry can alter emitted dose and lung deposition.

Which companies could challenge Tyvaso DPI?

Potential challengers fall into four groups:

Generic pharmaceutical companies

Large generic companies may evaluate an ANDA or 505(b)(2) route for inhaled treprostinil. Their main constraints are device replication, comparative performance, and patent litigation.

Inhalation specialists

Companies with dry-powder, soft-mist, or nebulizer expertise may develop a differentiated delivery system. They could avoid direct FDKP dependence but would need clinical and commercial evidence.

Treprostinil competitors

United Therapeutics competes with other pulmonary hypertension therapies, including oral, injectable, and inhaled agents. These products do not directly replicate Tyvaso DPI but can reduce the commercial value of a Tyvaso conversion strategy.

Platform licensors

MannKind's Technosphere technology remains strategically important. Licensing the platform for another pulmonary drug could create a competing product or strengthen the value of FDKP as a multi-product inhalation excipient.

What litigation and settlement risks affect generic entry?

The main litigation issues would likely involve:

• Invalidity of FDKP formulation claims
• Obviousness of treprostinil dry-powder combinations
• Infringement by particle-size and dose claims
• Device and cartridge claim scope
• Manufacturing-process infringement
• Written-description and enablement challenges
• Orange Book listing disputes
• Induced infringement based on labeled pulmonary hypertension uses

A settlement could specify a later generic launch date, an authorized generic arrangement, a license to use the platform, or a restriction limited to particular indications. Settlement economics would depend on Tyvaso revenue, the strength of the listed patents, expected first-filer exclusivity, and the cost of developing a non-FDKP alternative.

How does Tyvaso DPI compare with nebulized Tyvaso?

Attribute	Tyvaso DPI	Nebulized Tyvaso
Active ingredient	Treprostinil	Treprostinil
Formulation	Dry powder with FDKP	Inhalation solution
Administration	Portable inhaler and cartridge	Nebulizer
Excipient strategy	Engineered FDKP particle system	Liquid formulation excipients
Patient burden	Lower handling and treatment time	Greater equipment and preparation burden
Generic pathway	Complex inhalation equivalence	More conventional but still device-dependent
Lifecycle role	Newer franchise product	Original inhaled product
Patent risk	Excipient, particle, device and method claims	Solution, device and method claims

Tyvaso DPI is commercially positioned as a convenience-driven successor and complement to nebulized Tyvaso. The excipient strategy enables a substantial formulation change while preserving the treprostinil brand and clinical franchise.

What manufacturing and IP barriers exist?

The principal manufacturing barrier is reproducibility. FDKP-based powders must maintain consistent drug loading, particle structure, moisture, emitted dose, and aerodynamic performance at commercial scale.

Key barriers include:

• Specialized spray-drying and particle-engineering equipment
• Inhalation-grade analytical methods
• Low-dose content-uniformity controls
• Powder and cartridge compatibility
• Device assembly and fill-finish integration
• Stability under humidity exposure
• FDKP impurity and residual-solvent controls
• Patent access or design-around capability
• Clinical bridging for a new delivery system

For investors and business-development teams, the most valuable diligence questions concern platform dependency, alternative-source qualification, patent expiry, Orange Book scope, and whether a prospective entrant can pursue an ANDA rather than a full or partial clinical development program.

Key Takeaways

• Tyvaso DPI uses treprostinil in an FDKP-based dry-powder inhalation system.
• FDKP is strategically important because it supports particle formation and aerosol delivery.
• The competitive barrier is the combined excipient, particle-engineering, device, cartridge, and manufacturing system.
• Tyvaso DPI received FDA approval in May 2022 and had five-year new-drug exclusivity extending approximately through May 2027, subject to applicable regulatory treatment.
• A generic applicant may face a difficult ANDA pathway if it cannot match the formulation and device or establish pharmaceutical equivalence.
• A non-FDKP competitor could reduce patent exposure but would face greater clinical and regulatory development risk.
• The most direct commercial opportunities are FDKP supply, inhalation-grade particle engineering, device manufacturing, alternative excipient systems, and regional supply-chain qualification.
• Treprostinil is a small molecule, so biosimilar risk does not apply. The relevant competitive threats are generics, 505(b)(2) products, and differentiated inhaled formulations.

FAQs

Is FDKP a carrier or an active pharmaceutical ingredient in Tyvaso DPI?

FDKP is an inactive pharmaceutical excipient. It functions as the particle-forming and drug-delivery component of the inhalation powder.

Can a generic Tyvaso DPI use lactose instead of FDKP?

A competitor could develop a lactose-based product, but it would need to establish equivalent or clinically acceptable delivery performance. The change could prevent an ANDA from relying on simple equivalence and may require a 505(b)(2) or other regulatory strategy.

Does Tyvaso DPI have biosimilar competition?

No. Treprostinil is a small-molecule drug. Competition would arise through generic, hybrid, or independently developed inhaled products rather than biosimilars.

Why is the Tyvaso DPI inhaler relevant to excipient patent analysis?

The inhaler controls powder dispersion and delivered dose. A formulation that performs differently in the device may not be therapeutically or pharmaceutically equivalent, and device claims can create separate infringement risks.

Can FDKP be used in other pulmonary medicines?

Yes. FDKP is a platform excipient associated with MannKind's Technosphere technology. Its use in other products may require separate formulation development, licensing, regulatory qualification, and patent analysis.

References

1. U.S. Food and Drug Administration. (2024). Tyvaso DPI (treprostinil) inhalation powder: Prescribing information. United Therapeutics Corporation.

2. MannKind Corporation. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

3. United Therapeutics Corporation. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov

5. U.S. Food and Drug Administration. (2023). Approved drug products and patent certifications under the Hatch-Waxman Act. https://www.fda.gov